FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles.
Daniel A. King, MD, PhD
Advertisement
Articles by Daniel A. King, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sac-TMT Plus Pembrolizumab Beats Chemo-Immunotherapy in PD-L1–Negative NSCLC
2
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
3
Pembro Monotherapy Boosts PFS Vs Chemo in dMMR Endometrial Cancer
4
Vitamin D Use Tied to Longer Treatment-Free Survival in Early-Stage CLL
5